Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib with Docetaxel and Prednisone in HRPC
NCT02182219Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2005
- Primary completion
- Apr 2007
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in castration-resistant prostate cancer (CRPC), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose and Incidence and intensity of Adverse Events up to 6 months. Started Nov 2005; status: completed.
02
Drugs
nintedanib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02182219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182219.